Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Caveat emptor: Fellowship Training in Radiation Oncology: What, But More Importantly, Why?

Wallner PE, Rosenzweig KE, Vapiwala N.

Int J Radiat Oncol Biol Phys. 2019 Oct 19. pii: S0360-3016(19)33870-2. doi: 10.1016/j.ijrobp.2019.10.003. [Epub ahead of print] No abstract available.

PMID:
31647970
2.

Training and Education Requirements for Authorized Users of Therapeutic Radiopharmaceuticals: Changes Under Consideration for 10CFR35.390 and Their Potential Impact.

Wallner PE, Lieto RP, Dillehay GL, Ghesani MV, Rosenthal SA, Rosenzweig KE, Steinberg ML, Yoo DC.

J Am Coll Radiol. 2019 Nov;16(11):1572-1576. doi: 10.1016/j.jacr.2019.04.010. Epub 2019 May 16.

PMID:
31092343
3.

von Willebrand Factor Gene Expression in Primary Lower Grade Glioma: Mutually Co-Occurring Mutations in von Willebrand Factor, ATRX, and TP53.

Lehrer S, Rheinstein PH, Green S, Rosenzweig KE.

Brain Tumor Res Treat. 2019 Apr;7(1):33-38. doi: 10.14791/btrt.2019.7.e20.

4.

Increased RNA Expression of von Willebrand Factor Gene Is Associated With Infiltrating Lobular Breast Cancer and Normal PAM50 Subtype.

Lehrer S, Green S, Dembitzer FR, Rheinstein PH, Rosenzweig KE.

Cancer Genomics Proteomics. 2019 May-Jun;16(3):147-153. doi: 10.21873/cgp.20120.

5.

The evolving toxicity profile of SBRT for lung cancer.

Thompson M, Rosenzweig KE.

Transl Lung Cancer Res. 2019 Feb;8(1):48-57. doi: 10.21037/tlcr.2018.10.06. Review.

6.

Dual Modality Radiation With External Beam Radiation Therapy and Transarterial Radioembolization for Hepatocellular Carcinoma With Gross Vascular Invasion.

McGee HM, King MJ, Özbek U, Olson A, Kim E, Fischman AM, Schwartz M, Rosenzweig KE, Buckstein M.

Am J Clin Oncol. 2019 Apr;42(4):367-374. doi: 10.1097/COC.0000000000000523.

PMID:
30724782
7.

Dosimetric Correlates of Pulmonary Toxicity in Patients with Malignant Pleural Mesothelioma Receiving Radiation Therapy to the Intact Lungs.

Thompson MR, Dumane VA, Lazarev SA, Zia Y, Rosenzweig KE.

Pract Radiat Oncol. 2019 May;9(3):e331-e337. doi: 10.1016/j.prro.2018.12.008. Epub 2019 Jan 15.

PMID:
30654090
8.

Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database.

Van Gerwen M, Alpert N, Wolf A, Ohri N, Lewis E, Rosenzweig KE, Flores R, Taioli E.

Carcinogenesis. 2019 Jun 10;40(4):529-536. doi: 10.1093/carcin/bgz004.

PMID:
30649229
9.

Allergy may confer better survival on patients with gliomas.

Lehrer S, Rheinstein PH, Rosenzweig KE.

Clin Neurol Neurosurg. 2019 Feb;177:63-67. doi: 10.1016/j.clineuro.2018.12.021. Epub 2018 Dec 31.

10.

No Relationship of Anti-Androgens to Alzheimer's Disease or Cognitive Disorder in the MedWatch Database.

Lehrer S, Rheinstein PH, Rosenzweig KE.

J Alzheimers Dis Rep. 2018 Jun 30;2(1):123-127. doi: 10.3233/ADR-180052.

11.

Increased expression of von Willebrand factor gene is associated with poorer survival in primary lower grade glioma.

Lehrer S, Rheinstein PH, Rosenzweig KE.

Glioma. 2018 Jul-Aug;1(4):132-135. doi: 10.4103/glioma.glioma_17_18. Epub 2018 Aug 30.

12.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

13.

Loss of MycBP may be associated with the improved survival in 1P co-deletion of lower grade glioma patients.

Lehrer S, Rheinstein PH, Rosenzweig KE.

Clin Neurol Neurosurg. 2018 Sep;172:112-115. doi: 10.1016/j.clineuro.2018.07.003. Epub 2018 Jul 5.

PMID:
29986195
14.

Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the SGK1 Gene Are Associated with Poorer Survival.

Lehrer S, Rheinstein PH, Rosenzweig KE.

Cancer Genomics Proteomics. 2018 Jul-Aug;15(4):273-278. doi: 10.21873/cgp.20085.

15.

Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).

von Reibnitz D, Shaikh F, Wu AJ, Treharne GC, Dick-Godfrey R, Foster A, Woo KM, Shi W, Zhang Z, Din SU, Gelblum DY, Yorke ED, Rosenzweig KE, Rimner A.

Acta Oncol. 2018 Nov;57(11):1567-1573. doi: 10.1080/0284186X.2018.1481292. Epub 2018 Jun 6.

16.

In primary glioblastoma fewer tumor copy number segments of the F13A1 gene are associated with poorer survival.

Lehrer S, Dembitzer FR, Rheinstein PH, Rosenzweig KE.

Thromb Res. 2018 Jul;167:12-14. doi: 10.1016/j.thromres.2018.05.001. Epub 2018 May 4. No abstract available.

PMID:
29753279
17.

Mutations of the PDE5A Gene Confer a Survival Advantage in Patients with Colon Cancer.

Lehrer S, Rheinstein PH, Rosenzweig KE.

Cancer Prev Res (Phila). 2018 Jul;11(7):439-440. doi: 10.1158/1940-6207.CAPR-18-0105. Epub 2018 May 3. No abstract available.

18.

Periodontal Disease and Incident Cancer-Letter.

Lehrer S, Rheinstein PH, Rosenzweig KE.

Cancer Epidemiol Biomarkers Prev. 2018 May;27(5):614-615. doi: 10.1158/1055-9965.EPI-17-0726. No abstract available.

19.

Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.

Lehrer S, Rheinstein PH, Rosenzweig KE.

Cancer. 2018 May 15;124(10):2253. doi: 10.1002/cncr.31262. Epub 2018 Mar 15. No abstract available.

20.

Patterns of failure in limited-stage small cell lung cancer: Implications of TNM stage for prophylactic cranial irradiation.

Wu AJ, Gillis A, Foster A, Woo K, Zhang Z, Gelblum DY, Downey RJ, Rosenzweig KE, Ong L, Perez CA, Pietanza MC, Krug L, Rudin CM, Rimner A.

Radiother Oncol. 2017 Oct;125(1):130-135. doi: 10.1016/j.radonc.2017.07.019. Epub 2017 Aug 1.

21.

Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy.

Sonnick MA, Oro F, Yan B, Desai A, Wu AJ, Shi W, Zhang Z, Gelblum DY, Paik PK, Yorke ED, Rosenzweig KE, Chaft JE, Rimner A.

Clin Lung Cancer. 2018 Jan;19(1):e131-e140. doi: 10.1016/j.cllc.2017.06.019. Epub 2017 Jul 6.

PMID:
28756051
22.

Risk of malignant brain tumor as a second primary is significantly reduced after treatment of breast cancer.

Lehrer S, Green S, Rosenzweig KE.

Breast J. 2018 Mar;24(2):219-220. doi: 10.1111/tbj.12880. Epub 2017 Jul 20. No abstract available.

23.

Malignant pleural mesothelioma: adjuvant therapy with radiation therapy.

Rosenzweig KE.

Ann Transl Med. 2017 Jun;5(11):242. doi: 10.21037/atm.2017.06.25. Review.

24.

Association of Radon Background and Total Background Ionizing Radiation with Alzheimer's Disease Deaths in U.S. States.

Lehrer S, Rheinstein PH, Rosenzweig KE.

J Alzheimers Dis. 2017;59(2):737-741. doi: 10.3233/JAD-170308.

PMID:
28671130
25.

Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.

Shaikh F, Zauderer MG, von Reibnitz D, Wu AJ, Yorke ED, Foster A, Shi W, Zhang Z, Adusumilli PS, Rosenzweig KE, Krug LM, Rusch VW, Rimner A.

J Thorac Oncol. 2017 Jun;12(6):993-1000. doi: 10.1016/j.jtho.2017.02.026. Epub 2017 Mar 21.

26.

Definitive Radiotherapy for Local Recurrence of NSCLC After Surgery.

Wu AJ, Garay E, Foster A, Hsu M, Zhang Z, Chaft JE, Huang J, Rosenzweig KE, Rimner A.

Clin Lung Cancer. 2017 May;18(3):e161-e168. doi: 10.1016/j.cllc.2017.01.014. Epub 2017 Feb 21.

27.

Radiation therapy for malignant pleural mesothelioma.

Rosenzweig KE, Giraud P.

Cancer Radiother. 2017 Feb;21(1):73-76. doi: 10.1016/j.canrad.2016.09.009. Epub 2017 Feb 23. Review.

PMID:
28237609
28.

Influenza vaccination in patients with cancer.

Lehrer S, Rosenzweig KE.

Cancer. 2017 Apr 1;123(7):1272-1273. doi: 10.1002/cncr.30612. Epub 2017 Feb 9. No abstract available.

29.
30.

Concurrent Chemotherapy and Radiation Therapy for Inoperable Locally Advanced Non-Small-Cell Lung Cancer.

Rosenzweig KE, Gomez JE.

J Clin Oncol. 2017 Jan;35(1):6-10. Epub 2016 Nov 21. Review.

PMID:
27870565
32.

Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.

Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, Wu AJ, Woo KM, Shen R, Ginsberg MS, Yorke ED, Rice DC, Tsao AS, Rosenzweig KE, Rusch VW, Krug LM.

J Clin Oncol. 2016 Aug 10;34(23):2761-8. doi: 10.1200/JCO.2016.67.2675. Epub 2016 Jun 20.

33.

Cost of Intensity-modulated Radiation Therapy for Older Patients with Stage III Lung Cancer.

Kale MS, Mhango G, Bonomi M, Federman A, Sigel K, Rosenzweig KE, Wisnivesky JP.

Ann Am Thorac Soc. 2016 Sep;13(9):1593-9. doi: 10.1513/AnnalsATS.201603-156OC.

34.

Affluence and Breast Cancer.

Lehrer S, Green S, Rosenzweig KE.

Breast J. 2016 Sep;22(5):564-7. doi: 10.1111/tbj.12630. Epub 2016 Jun 14.

35.

Being a widower may be an indication for routine prostate-specific antigen screening above age 69 years, which the American Urological Association recommends as a cutoff point.

Lehrer S, Rosenzweig KE.

Cancer. 2016 Aug 15;122(16):2604. doi: 10.1002/cncr.30098. Epub 2016 Jun 10. No abstract available.

36.

Periodontal Disease and Breast Cancer-Letter.

Lehrer S, Green S, Rosenzweig KE.

Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):863. doi: 10.1158/1055-9965.EPI-16-0033. No abstract available.

37.

Geometric dose prediction model for hemithoracic intensity-modulated radiation therapy in mesothelioma patients with two intact lungs.

Kuo L, Yorke ED, Dumane VA, Foster A, Zhang Z, Mechalakos JG, Wu AJ, Rosenzweig KE, Rimner A.

J Appl Clin Med Phys. 2016 May;17(3):371-379. doi: 10.1120/jacmp.v17i3.6199.

38.

Scientific Advances in Lung Cancer 2015.

Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI.

J Thorac Oncol. 2016 May;11(5):613-638. doi: 10.1016/j.jtho.2016.03.012. Epub 2016 Mar 22. Review.

39.

Robust breathing signal extraction from cone beam CT projections based on adaptive and global optimization techniques.

Chao M, Wei J, Li T, Yuan Y, Rosenzweig KE, Lo YC.

Phys Med Biol. 2016 Apr 21;61(8):3109-26. doi: 10.1088/0031-9155/61/8/3109. Epub 2016 Mar 23.

40.

The use of isodose levels to interpret radiation induced lung injury: a quantitative analysis of computed tomography changes.

Knoll MA, Salvatore M, Sheu RD, Knoll AD, Kerns SL, Lo YC, Rosenzweig KE.

Quant Imaging Med Surg. 2016 Feb;6(1):35-41. doi: 10.3978/j.issn.2223-4292.2016.02.07.

41.

High- and low-dose-rate intraoperative radiotherapy for thoracic malignancies resected with close or positive margins.

Fleming C, Rimner A, Cohen GN, Woo KM, Zhang Z, Rosenzweig KE, Alektiar KM, Zelefsky MJ, Bains MS, Wu AJ.

Brachytherapy. 2016 Mar-Apr;15(2):208-15. doi: 10.1016/j.brachy.2015.11.007. Epub 2016 Jan 26.

42.

Melanoma Risk and Citrus Consumption.

Lehrer S, Green S, Rosenzweig KE.

J Clin Oncol. 2016 Feb 20;34(6):636. doi: 10.1200/JCO.2015.63.8254. Epub 2016 Jan 4. No abstract available.

PMID:
26729433
43.

Measles may be a Risk Factor for Malignant Brain Tumors.

Lehrer S, Green S, Rendo A, Rosenzweig KE.

Brain Tumor Res Treat. 2015 Oct;3(2):65-7. doi: 10.14791/btrt.2015.3.2.65. Epub 2015 Oct 30.

44.

Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer: Implications for Surveillance.

Spratt DE, Wu AJ, Adeseye V, Din SU, Shaikh F, Woo KM, Zhang Z, Foster A, Rosenzweig KE, Gewanter R, Huang J, Rimner A.

Clin Lung Cancer. 2016 May;17(3):177-183.e2. doi: 10.1016/j.cllc.2015.09.006. Epub 2015 Oct 1.

45.

Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree.

Haseltine JM, Rimner A, Gelblum DY, Modh A, Rosenzweig KE, Jackson A, Yorke ED, Wu AJ.

Pract Radiat Oncol. 2016 Mar-Apr;6(2):e27-33. doi: 10.1016/j.prro.2015.09.012. Epub 2015 Nov 11.

46.

Measles may be a Risk Factor for Malignant Brain Tumors.

Lehrer S, Green S, Rendo A, Rosenzweig KE.

Brain Tumor Res Treat. 2015 Oct 31;3:65-67.

PMID:
26568950
47.

Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer.

Ong LT, Dunphy M, Foster A, Woo KM, Zhang Z, Perez CA, Pietanza CM, Rosenzweig KE, Gelblum DY, Rimner A, Wu AJ.

Clin Lung Cancer. 2016 May;17(3):184-8. doi: 10.1016/j.cllc.2015.07.004. Epub 2015 Aug 3.

48.

A Feasibility Study of Tumor Motion Estimate With Regional Deformable Registration Method for 4-Dimensional Radiation Therapy of Lung Cancer.

Chao M, Yuan Y, Sheu RD, Wang K, Rosenzweig KE, Lo YC.

Technol Cancer Res Treat. 2016 Oct;15(5):NP8-NP16. doi: 10.1177/1533034615600569. Epub 2015 Aug 20.

PMID:
26294654
49.

Impact of Fractionation and Dose in a Multivariate Model for Radiation-Induced Chest Wall Pain.

Din SU, Williams EL, Jackson A, Rosenzweig KE, Wu AJ, Foster A, Yorke ED, Rimner A.

Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):418-24. doi: 10.1016/j.ijrobp.2015.06.014. Epub 2015 Jun 14.

50.

Outcomes after Stereotactic Body Radiotherapy versus Limited Resection in Older Patients with Early-Stage Lung Cancer.

Ezer N, Veluswamy RR, Mhango G, Rosenzweig KE, Powell CA, Wisnivesky JP.

J Thorac Oncol. 2015 Aug;10(8):1201-6. doi: 10.1097/JTO.0000000000000600.

Supplemental Content

Loading ...
Support Center